Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study

被引：2
|
作者：
Wang Feng [1 ]
Wang Junsheng [2 ]
Wu Tao [2 ]
Hong Yonggui [2 ]
Meng Xiangrui [1 ]
Ren Zhonghai [3 ]
Guo Yanzhen [4 ]
Yang Xiuli [5 ]
Shi Pei [5 ]
Yang Jiamei [6 ]
Fan Qingxia [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[2] AnYang Tumor Hosp, Anyang, Peoples R China
[3] Nanyang Cent Hosp, Nanyang, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[5] Nanyang Med Coll, Affiliated Hosp 1, Nanyang, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 2, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
215
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Paclitaxel and cisplatin combined with anlotinib as first line regimen for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicentre open-label phase II clinical trial
    Wang, J-S.
    Wu, T.
    Hong, Y-G.
    Guo, Y-Z.
    Luo, S-X.
    Li, N.
    Cheng, Y-F.
    Li, B-S.
    ANNALS OF ONCOLOGY, 2020, 31 : S910 - S911
  • [42] Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II Study
    Spigel, David R.
    Waterhouse, David M.
    Lane, Steve
    Legenne, Philippe
    Bhatt, Kamal
    CLINICAL LUNG CANCER, 2013, 14 (04) : 356 - 363
  • [43] Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study
    Zhi-Qiang Wang
    De-Shen Wang
    Feng-Hua Wang
    Chao Ren
    Qiong Tan
    Yu-Hong Li
    Investigational New Drugs, 2021, 39 : 516 - 523
  • [44] Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study
    Wang, Zhi-Qiang
    Wang, De-Shen
    Wang, Feng-Hua
    Ren, Chao
    Tan, Qiong
    Li, Yu-Hong
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (02) : 516 - 523
  • [45] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial
    Chang, Zhiwei
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Wang, Rui-Rui
    Qin, Yan-ru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 340 - 340
  • [46] An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
    Agulnik, Mark
    Schulte, Brian
    Robinson, Steven
    Hirbe, Angela C.
    Kozak, Kevin
    Chawla, Sant P.
    Attia, Steven
    Rademaker, Alfred
    Zhang, Hui
    Abbinanti, Susan
    Cehic, Rasima
    Monga, Varun
    Milhem, Mohammed
    Okuno, Scott
    Van Tine, Brian A.
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 201 - 208
  • [47] Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial
    Zhao, Wensi
    Ke, Shaobo
    Cai, Xiaojun
    Zuo, Zhigang
    Shi, Wei
    Qiu, Hu
    Cai, Gaoke
    Gong, Yi
    Wu, Yong
    Ruan, Shasha
    Chen, Yongshun
    RADIOTHERAPY AND ONCOLOGY, 2023, 184
  • [48] Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1ST-RT): A single-arm, open-label, phase II trial
    Huang, W.
    Han, D.
    Li, B.
    Dong, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S902 - S902
  • [49] Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
    Finn, Richard S.
    Kang, Yoon-Koo
    Mulcahy, Mary
    Polite, Blase N.
    Lim, Ho Yeong
    Walters, Ian
    Baudelet, Christine
    Manekas, Demetrios
    Park, Joong-Won
    CLINICAL CANCER RESEARCH, 2012, 18 (07) : 2090 - 2098
  • [50] Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial
    Wu, Zixiang
    Wu, Chuanqiang
    Zhao, Jing
    Wu, Cong
    Peng, Haixian
    Wang, Qi
    Bai, Rui
    Fang, Xuefeng
    He, Hong
    Shen, Hong
    Wu, Ming
    ECLINICALMEDICINE, 2024, 71
12345